source
- Vera Therapeutics' Trutakna shows kidney function stabilization and lower death risk in Phase 3 IgAN trialVera Therapeutics reported that its drug Trutakna met its primary goals in a two‑year Phase 3 study of patients with IgA nephropathy. The therapy stabilized kidney function and lowered the risk of…
- GSK licenses Chimagen trispecific T-cell engager for up to $750 million, targeting phase-1 multiple myeloma studyGSK has entered a licensing agreement with China’s Chimagen Biosciences that could be worth as much as $750 million. The deal will allow GSK to begin phase‑1 testing of a trispecific T‑cell engager…